{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:36:45Z","timestamp":1778812605076,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T00:00:00Z","timestamp":1372896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Peptides"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.regpep.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T08:02:53Z","timestamp":1368086573000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Effects of lixisenatide once daily on gastric emptying in type 2 diabetes \u2014 Relationship to postprandial glycemia"],"prefix":"10.1016","volume":"185","author":[{"given":"Martin","family":"Lorenz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Steinstr\u00e4\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard H.A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"R\u00fctten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ruus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.regpep.2013.04.001_bb0005","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.regpep.2013.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.regpep.2013.04.001_bb0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications","volume":"124","author":"Nauck","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.regpep.2013.04.001_bb0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.regpep.2013.04.001_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","article-title":"Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes","volume":"151","author":"Linnebjerg","year":"2008","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2013.04.001_bb0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF00400362","article-title":"Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects","volume":"36","author":"Horowitz","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2013.04.001_bb0035","first-page":"1643","article-title":"Gastric emptying in early noninsulin-dependent diabetes mellitus","volume":"37","author":"Jones","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.regpep.2013.04.001_bb0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1023\/A:1022528414264","article-title":"Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients","volume":"48","author":"Gonlachanvit","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.regpep.2013.04.001_bb0045","doi-asserted-by":"crossref","first-page":"279530","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.regpep.2013.04.001_bb0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0950-3528(91)90034-X","article-title":"Disordered gastric emptying: mechanical basis, assessment and treatment","volume":"5","author":"Horowitz","year":"1991","journal-title":"Baillieres Clin Gastroenterol"},{"key":"10.1016\/j.regpep.2013.04.001_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2337\/diacare.24.2.371","article-title":"Relationships of upper gastrointestinal motor and sensory function with glycemic control","volume":"24","author":"Rayner","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.regpep.2013.04.001_bb0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/CCM.0b013e3181d9d87a","article-title":"Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia","volume":"38","author":"Deane","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.regpep.2013.04.001_bb0065","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2005-2220","article-title":"Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses","volume":"91","author":"Little","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0070","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2013.04.001_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","article-title":"The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients","volume":"28","author":"Flint","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.regpep.2013.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.regpep.2013.04.001_bb0085","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","article-title":"Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ratner","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.regpep.2013.04.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with T2DM inadequately controlled with metformin","author":"Kapitza","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0095","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.regpep.2013.04.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","author":"Pinget","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0105","series-title":"Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes","first-page":"1","article-title":"Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1)","volume":"54","author":"Bolli","year":"2011"},{"key":"10.1016\/j.regpep.2013.04.001_bb0110","series-title":"Diabetes Care","article-title":"Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)","author":"Ahr\u00e9n","year":"2013"},{"key":"10.1016\/j.regpep.2013.04.001_bb0115","series-title":"Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12\u201316 September 2011, Lisbon, Portugal","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea\u00b1metformin (GetGoal-S)","volume":"54","author":"Ratner","year":"2011"},{"key":"10.1016\/j.regpep.2013.04.001_bb0120","series-title":"Diabetes Care","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-Week, Randomized, Placebo-Controlled Study (GetGoal-Duo 1)","author":"Riddle","year":"2013"},{"key":"10.1016\/j.regpep.2013.04.001_bb0125","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.regpep.2013.04.001_bb0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/0016-5085(93)90640-X","article-title":"Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test","volume":"104","author":"Ghoos","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.regpep.2013.04.001_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.regpep.2013.04.001_bb0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.diabres.2006.11.011","article-title":"Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels","volume":"77","author":"Woerle","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.regpep.2013.04.001_bb0155","author":"2011 Guideline for Management of PostMeal Glucose in Diabetes","year":"2011","journal-title":"International Diabetes Federation"},{"key":"10.1016\/j.regpep.2013.04.001_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-8-23","article-title":"Postprandial hyperglycemia as an etiological factor in vascular failure","volume":"8","author":"Node","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.regpep.2013.04.001_bb0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","article-title":"Liraglutide: short-lived effect on gastric emptying \u2014 long lasting effects on body weight","volume":"14","author":"Jelsing","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0170","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1152\/ajpendo.90222.2008","article-title":"Exenatide can reduce glucose independent of islet hormones or gastric emptying","volume":"295","author":"Ionut","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.regpep.2013.04.001_bb0175","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2013.04.001_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.regpep.2013.04.001_bb0190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.103.051987","article-title":"Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db\/db mice","volume":"307","author":"Thorkildsen","year":"2003","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Regulatory Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167011513000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167011513000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:23:28Z","timestamp":1539649408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167011513000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":36,"alternative-id":["S0167011513000773"],"URL":"https:\/\/doi.org\/10.1016\/j.regpep.2013.04.001","relation":{},"ISSN":["0167-0115"],"issn-type":[{"value":"0167-0115","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes \u2014 Relationship to postprandial glycemia","name":"articletitle","label":"Article Title"},{"value":"Regulatory Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.regpep.2013.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}